Prof. Schultz (1965) began his professional career when he joined the Department of Intensive Care in 2000 after completing a fellowship in Critical Care at the Amsterdam UMC (location AMC). Widely known and admired for his scientific productivity, he is one of the most highly cited Critical Care researchers in the world.

He is a founding member of the PROtective VENTilation Network, a group of international experts that performed several highly cited international multicenter randomized clinical trials of invasive ventilation, in surgery patients in the operating room, and in critically ill patients in the intensive care unit, and of CRIT CARE ASIA, a group of international experts that perform studies in intensive care units in resource-limited settings.

As a faculty member in the Department of Intensive Care at the Amsterdam UMC (location AMC), he is extensively sponsored by the ‘Netherlands Organization for Health Research and Development’ (NWO, ZonMw) since 2005. In 2006 he established the 'Laboratory of Experimental Intensive Care & Anesthesiology' (L·E·I·C·A). Dr. Schultz holds the Endowed Chair in Experimental Intensive Care at the University of Amsterdam since 2008. He oversaw enormous growth in research activity and optimized the operations of the research team in recent years. He currently works in close collaboration with the research groups in Dresden, Genova and Vienna.

He served as a leading investigator of numerous observational studies and randomized clinical trials (RCTs) in ICU and surgery patients, in high-income and low/middle-income countries, including the observational studies 'LAS VEGAS', 'LAMiNAR', 'COURSE', 'PRoVENT', 'PRoVENT-iMiC', 'PRoVENT-COVID', 'PRoAcT-COVID', 'PRoVaCT-COVID', 'PROXY-COVID', 'ENIRI', 'ENIO', 'BreathDx', 'DARTS', 'LUXoR', 'PRoFLUID/PRoFLUID-iMiC', and 'MARS/MARS-BASIC', the RCTs 'PROVHILO', 'PROBESE', 'PROTHOR', 'DESIGNATION', 'GENERATOR', 'HEPBURN', 'HiLoNALI', 'HiLoHeLu', 'PReVENT', 'NEBULAE', 'RELAx', 'ACTiVE', 'INTELLiSTREAM', 'AiRDRoP', 'PERFuSE', 'INTELLiPOWER', 'CONFIDENCE', and 'PEGASUS', and the individual patient data-analysis 'REPEAT', and 'PRoVENT-COP'. Soon two new studies are about to start, 'PRoVENT/WEAN-PED' and 'BIG APPLE', and a new trial is under development, named 'PERMISS'. Last but not least, he’s one of the leading researchers in the famICom project.